$214 Million is the total value of DAFNA Capital Management LLC's 75 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MNLO | New | MENLO THERAPEUTICS INC | $2,533,000 | – | 312,000 | +100.0% | 1.19% | – |
| New | INTEC PHARMA LTD JERUSALEM | $2,502,000 | – | 568,600 | +100.0% | 1.17% | – | |
| CSII | New | CARDIOVASCULAR SYSTEMS INC | $1,915,000 | – | 59,200 | +100.0% | 0.90% | – |
| ZFGN | New | ZAFGEN INC | $1,671,000 | – | 163,377 | +100.0% | 0.78% | – |
| DRNA | New | DICERNA PHARMACEUTICALS INC | $1,348,000 | – | 110,000 | +100.0% | 0.63% | – |
| NVAX | New | NOVAVAX INC | $1,005,000 | – | 750,000 | +100.0% | 0.47% | – |
| BHVN | New | BIOHAVEN PHARMACEUTICALS HOLD | $929,000 | – | 23,500 | +100.0% | 0.44% | – |
| NTGN | New | NEON THERAPEUICS INC | $630,000 | – | 50,000 | +100.0% | 0.30% | – |
| BLUE | New | BLUEBIRD BIO INC | $628,000 | – | 4,000 | +100.0% | 0.29% | – |
| APTX | New | APTINYX INC | $604,000 | – | 25,000 | +100.0% | 0.28% | – |
| GLMD | New | GALMED PHARMACEUTICALS LTD | $595,000 | – | 50,000 | +100.0% | 0.28% | – |
| CYTK | New | CYTOKINETICS INC | $576,000 | – | 69,437 | +100.0% | 0.27% | – |
| RDUS | New | RADIUS HEALTH INC | $295,000 | – | 10,000 | +100.0% | 0.14% | – |
| New | DEXCOM INCdbcv 0.750% 5/1 | $288,000 | – | 250,000 | +100.0% | 0.14% | – | |
| KDMN | New | KADMON HOLDINGS INC | $261,000 | – | 65,500 | +100.0% | 0.12% | – |
| TBIO | New | TRANSLATE BIO INC | $253,000 | – | 20,000 | +100.0% | 0.12% | – |
| BLCM | New | BELLICUM PHARMACEUTICALS INC | $221,000 | – | 30,000 | +100.0% | 0.10% | – |
| FTSV | New | FORTY SEVEN INC | $160,000 | – | 10,000 | +100.0% | 0.08% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.